TRKing down drug resistance in NTRK fusion-positive cancers.
J Pathol
; 264(2): 129-131, 2024 Oct.
Article
en En
| MEDLINE
| ID: mdl-39072755
ABSTRACT
In a recent issue of The Journal of Pathology, Chen and colleagues established novel patient-derived ex vivo models of NTRK fusion-positive soft tissue sarcoma to characterize resistance mechanisms against targeted therapy with tyrosine kinase inhibitors. Prolonged exposure to escalating concentrations of the tyrosine kinase inhibitor, entrectinib, ultimately led to the occurrence of resistant clones that harbored an inactivating mutation in the NF2 gene, not previously described in this context, accompanied by increased PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling. Finally, an inhibitor screen identified, among others, MEK and mTOR inhibitors as potential combination agents. © 2024 The Pathological Society of Great Britain and Ireland.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Resistencia a Antineoplásicos
/
Inhibidores de Proteínas Quinasas
Límite:
Humans
Idioma:
En
Revista:
J Pathol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos